- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00249652
Transplant and Addiction Project (TAP) - 1
April 13, 2015 updated by: St. Luke's-Roosevelt Hospital Center
Drug Treatment for Transplant Candidates
The purpose of this study is to test a novel distance-based (telephone) intervention to help transplant candidates with current or recent substance abuse to stay "clean and sober" both prior and following transplant surgery.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Participants who need a liver or renal transplant and who are ineligible due to current or recent (past 6 months) alcohol and/or other drug abuse are being recruited from the transplant programs at St. Luke's-Roosevelt Hospital Center (renal), Columbia Presbyterian Hospital (renal/liver) and Virginia Commonwealth University Medical Center (liver).
Baseline and follow-up computer-assisted assessments and structured clinical interviews along with collection of biological samples (urine, hair) will occur in the transplant clinics; however, phone counseling sessions originate at St. Luke's.
Participants are randomly assigned to one of two treatments: (1) usual care (no phone counseling) or (2) usual care + counseling.
The telephone counseling sessions are designed to help participants become motivated to remain abstinent and improve other health behaviors such as sleep or stress management.
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10025
- Behavioral Science Research Unit
-
New York, New York, United States, 10032
- Renal & Islet Transplant, Center for Liver Disease
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Liver Transplant Program
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- End stage liver or renal disease
- Having used drugs or alcohol during the past 6 months
- Turned down for transplant due to current or recent substance use
- Access to telephone
Exclusion Criteria:
- Psychotic or other unstable serious psychiatric disorders that preclude full, active participation
- Moderate to severe hepatic encephalopathy
- Non-English speaking
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAP
MI-based phone intervention.
|
12-session motivational interviewing-based telephone intervention.
|
Other: TAU
Treatment As Usual
|
The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Abstinence
Time Frame: 3 month time frame
|
3 month time frame
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Stage of Change, illness response, psychological stress
Time Frame: 3 month time frame
|
3 month time frame
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Deborah Haller, St. Luke's Roosevelt Hosp Cntr (New York)
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Wagner CC, Haller DL, Olbrisch ME. Relapse prevention treatment for liver transplant patients. J Clin Psychol Med Settings. 1996 Dec;3(4):387-98. doi: 10.1007/BF01994021.
- Presented at the Ninth Annual International Liver Transplantation Society Congress, Barcelona, Spain, June 2003.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2003
Primary Completion (Actual)
June 1, 2009
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
November 3, 2005
First Submitted That Met QC Criteria
November 3, 2005
First Posted (Estimate)
November 7, 2005
Study Record Updates
Last Update Posted (Estimate)
April 14, 2015
Last Update Submitted That Met QC Criteria
April 13, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIDA-15772-1
- R01-15772-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance-Related Disorders
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Substance Use | Substance Use Disorders | Substance Abuse | Substance Dependence | Substance Related Problem
-
US Department of Veterans AffairsCompletedAlcoholism | Substance Use Disorders | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
VA Office of Research and DevelopmentRecruiting
-
National Institute on Drug Abuse (NIDA)CompletedSubstance-related Disorders
-
Norwegian University of Science and TechnologyCompletedSubstance-related DisordersNorway
-
University of Southern CaliforniaNational Institute on Drug Abuse (NIDA)Completed
-
University Hospital, Basel, SwitzerlandPsychiatric Hospital of the University of BaselCompleted
-
University of LuebeckFederal Ministry of Health, GermanyCompletedSubstance-related Disorders
-
University of Illinois at Urbana-ChampaignCompletedSubstance-related Disorders
-
University of NebraskaCompletedSubstance-related Disorders | Alcohol-related DisordersUnited States
Clinical Trials on TAP
-
Mansoura UniversityUnknownCholecystitis; GallstoneEgypt
-
Ankara City Hospital BilkentCompletedPostoperative Pain, Acute | Analgesia, Patient-ControlledTurkey
-
Indiana UniversityHalyard HealthCompleted
-
Johns Hopkins UniversityTerminatedDiabetic Retinopathy | Stargardt Disease | Macular Degeneration (Age Related)United States
-
St. Olavs HospitalKarolinska University Hospital; University Hospital of North Norway; Norwegian...WithdrawnCranial Nerve Diseases | Facial Neuralgia | Trigeminal Neuralgia | Hemifacial Spasm
-
University of ManitobaMitsubishi-Rayon-CleansuiUnknownFoot Ulcer | Critical Limb Ischemia | Critical Lower Limb Ischemia | Skin UlcerationCanada
-
Ente Ospedaliero Cantonale, BellinzonaRecruitingPlantar FascitisSwitzerland
-
Stanford UniversityUniversity of California, San FranciscoCompletedObesityUnited States
-
Aga Khan UniversityCompletedSubcostal TAP Block for Multiport Laparoscopic Cholecystectomy